Last autumn, I was searching for a way to get rid of the nerve-zapping pain that hit every time the barometer made a steep jump. My face full of post-plane crash titanium and regenerated bone acted like a weather station. I couldn’t find doctors with experience in my kind of injury. “Folks with injuries like yours are usually dead . . .” My husband turned to the military world, with the recent flood of soldiers with faces and other body parts that need rebuilding. He found a team at Lackland Air Force Base in Texas reporting on repairing maxillofacial trauma...
The steady drip, drip, drip of excess stomach acid experienced by biotech venture capitalists, institutional investors and employees is sadly in sync with the steady drip, drip, drip of capital away from the sector.
It's officially spring, and we made it past April Fool's Day still intact. News from the Middle East and the Pacific Rim is scary, but the stock market has had its best quarter in a while. So how did it work out for private biotech firms last quarter, and what might lie ahead? (BioWorld Perspectives)